Search by Drug Name or NDC

    NDC 75987-0080-10 Krystexxa 8 mg/mL Details

    Krystexxa 8 mg/mL

    Krystexxa is a INTRAVENOUS INJECTION, SOLUTION in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Horizon Therapeutics USA, Inc.. The primary component is PEGLOTICASE.

    Product Information

    NDC 75987-0080
    Product ID 75987-080_5cd1b348-e083-4b70-855b-eb440e5b4b57
    Associated GPIs 68000050002020
    GCN Sequence Number 066681
    GCN Sequence Number Description pegloticase VIAL 8 MG/ML INTRAVEN
    HIC3 C7G
    HIC3 Description HYPERURICEMIA TX - URATE-OXIDASE ENZYME-TYPE
    GCN 29038
    HICL Sequence Number 037154
    HICL Sequence Number Description PEGLOTICASE
    Brand/Generic Brand
    Proprietary Name Krystexxa
    Proprietary Name Suffix n/a
    Non-Proprietary Name pegloticase
    Product Type HUMAN PRESCRIPTION DRUG
    Dosage Form INJECTION, SOLUTION
    Route INTRAVENOUS
    Active Ingredient Strength 8
    Active Ingredient Units mg/mL
    Substance Name PEGLOTICASE
    Labeler Name Horizon Therapeutics USA, Inc.
    Pharmaceutical Class Urate Oxidase [CS], Uric Acid-specific Enzyme [EPC]
    DEA Schedule n/a
    Marketing Category BLA
    Application Number BLA125293
    Listing Certified Through 2024-12-31

    Package

    NDC 75987-0080-10 (75987008010)

    NDC Package Code 75987-080-10
    Billing NDC 75987008010
    Package 1 VIAL in 1 CARTON (75987-080-10) / 1 mL in 1 VIAL
    Marketing Start Date 2010-09-14
    NDC Exclude Flag N
    Pricing Information N/A